source
- CLL-321 Trial Efficacy and Safety Results AnalysisPhase 3 results: pirtobrutinib boosts PFS, delays next treatment after prior BTK therapy, and shows low cardiac toxicity.onclive · 2mo ago↗ source
- #ASGCT26: Tessera reveals strongest data yet for in vivo sickle cell therapyBOSTON — Tessera Therapeutics has created an experimental gene editing drug for sickle cell disease that could compete with commercial cell therapies but is delivered as an infusion — no complex ce…Endpoints · 2mo ago↗ source
- How Reimagined Research Endeavors Intersect With Dignified End-of-Life Care: With D. Ross Camidge, MD, PhD; and Charles D. Blanke, MD, FACP, FASCODrs Camidge and Blanke discuss Dr Blanke's career path from pioneering targeted cancer therapies to becoming a leading advocate for medical aid in dying.